

# Use of patient's own blood to help in the treatment of leprosy ulcers

<b>Submission date</b> 20/05/2020	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 16/06/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 03/05/2024	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Leprosy ulcers are not caused by the leprosy germ but by loss of sensation leading to repetitive injury. Treatment consists of keeping the ulcer clean and fresh and also applying wet bandages regularly (dressing changes). The purpose of this study is to test a new method that may help the ulcer to heal faster. The proposed treatment involves creating a membrane from the patient's blood and then placing this membrane over the ulcer during a dressing change. Patients will typically have dressing changes every 3 or 4 days. At present, this treatment appears to be very safe, although currently it is not known whether it is effective. This study only looks at ulcers on the feet or legs and not anywhere else.

Some people think ulcers heal faster using this membrane but others do not think so. It has not yet been properly tested. That is what this study aims to do, a 'fair test' to see if this membrane really does make healing faster.

### Who can participate?

Adult patients with ulcers on their legs or feet

### What does the study involve?

Participants are randomly allocated to one of two groups. One group will have blood taken from their vein in order to create a membrane. Participants in this group will have dressing changes every 3 or 4 days, during this a membrane will be placed over the ulcer. The second group will have dressing changes as normal without the membrane being created or placed.

### What are the possible benefits and risks of participating?

The possible risk for participants is an infection of the wound and anaemia (lowered numbers of red blood cells or a lowered ability of red blood cells to carry oxygen). But there is minimal chance of infection as we use the patient's own blood during the procedure, and we use vitamins (Iron and Folic acid) from the day of enrolment to prevent anaemia.

The possible benefit for the participants is fast healing of the wounds without any surgical procedure like skin grafts.

Where is the study run from?

The study is being conducted at and organised by the Anandaban Hospital, The Leprosy Mission Nepal (Nepal) in collaboration with the University of Birmingham (UK)

When is the study starting and how long is it expected to run for?

From July 2020 to December 2023

Who is funding the study?

The National Institute for Health Research (NIHR) Research and Innovation for Global Health Transformation (RIGHT) Programme (UK)

Who is the main contact?

Dr Indra Bahadur Napit

indran@TLMnepal.org

### **Study website**

<https://www.birmingham.ac.uk/research/bctu/trials/portfolio-v/table/index.aspx>

## **Contact information**

### **Type(s)**

Scientific

### **Contact name**

Dr Indra Bahadur Napit

### **Contact details**

Anandaban Hospital

The Leprosy Mission

Lalitpur

Nepal

44700

+977 9851136027

indran@TLMnepal.org

### **Type(s)**

Scientific

### **Contact name**

Prof Richard Lilford

### **ORCID ID**

<http://orcid.org/0000-0002-0634-984X>

### **Contact details**

University of Birmingham

Murray learning Centre

Edgbaston

Birmingham

United Kingdom

B15 2TT

+44(0)121 414 6772  
r.j.lilford@bham.ac.uk

## **Additional identifiers**

**EudraCT/CTIS number**  
Nil known

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
NIHR RIGHT Leprosy and BU Research Protocol WP3 Efficacy Trial, NHRC 303/2020 P

## **Study information**

**Scientific Title**  
Trial of Autologous Blood products to promote ulcer healing in LEprosy: TABLE

**Acronym**  
TABLE

**Study objectives**  
To evaluate the efficacy of L-PRF on healing rates for leprosy ulcers and on the duration of hospital stay in a randomised controlled trial.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Approved 20/05/2020, Science, Technology, Engineering and Mathematics Ethical Review Committee, University of Birmingham (Room 137 C Block Dome, Aston Webb Building, University of Birmingham, Edgbaston B15 2TT UK; +44 (0)121 414 8825; s.l.cottam@bham.ac.uk), ref: ERN\_19-1960

**Study design**  
Randomised controlled trial

**Primary study design**  
Interventional

**Secondary study design**  
Randomised controlled trial

**Study setting(s)**  
Hospital

**Study type(s)**

## Treatment

### Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

### Health condition(s) or problem(s) studied

Non-healing skin ulcers in patients with leprosy

### Interventions

Participants will be individually randomized at a ratio of 1:1 to one of two groups:

1. Platelet enriched plasma
2. Control

The patient enriched plasma intervention uses the patient's own blood to prepare strips of leukocyte and platelet-rich material (L-PRF) to apply to wounds. The maximum volume of blood taken at one time is 80ml depending on the size of the ulcer. Blood will be taken twice per week at the time of dressing change in the intervention group. The control group will have only Normal saline dressing. All patients (including those in the control group) will be given iron and folic acid tablets. Patients in both groups have twice-weekly dressing changes during their hospital stay until ulcers are healed. The whole procedure is done in line with universal safety precautions using sterile technique for procedure. Blood collection from patients, centrifuge procedure, and application of L-PRF is done in a minor operation room with sterile technique. All the patients will be followed up at 6 months from randomization.

### Randomization:

The randomization procedure will follow a "digital sealed envelope" method since patients are enrolled sequentially, over time, into the trial. An allocation table will be generated at the University of Birmingham by the trial statistician to give a 1:1 ratio to treatment and control groups over the course of the trial. A random number generator will be used to generate a random sequence of the numbers 1 to N which will be used to 'shuffle' the list of treatment and control indicators. No blocking or other modifications to this table will be used. The generated table will be uploaded into the REDCap software to be used for patient enrolment and baseline. Trial staff in Nepal will not have access to the allocation table. When a patient's details are irreversibly submitted, the trial arm and a unique study number will be assigned and revealed to the local clinician so that the randomized group that the patient is assigned to cannot be tampered with.

### Assessment:

Photographic data are collected at each dressing change – twice per week. The research fellow will record data at each of these dressing changes by completing a form on the electronic tablet. The type of treatment administered (i.e. intervention or control) will be recorded so that adherence to allocated treatment can be observed. A short clinical form will also be completed at each dressing change to record the clinical appearance of the wound (e.g. any residual exudate) and the time taken to complete the dressing change (from patient entering to leaving the room).

Ulcer metrics will be based on photographs taken during dressing changes in a standardised manner, as recommended in the literature. The photographs will be obtained in Nepal by researchers employed on the grant using the camera in the data collection tablet. A clean ruler is placed in the photograph frame at the level of the ulcer. The trial number will be linked

electronically to each frame. The photographs will be assessed completely independently of the local research site in Nepal by a research fellow at the University of Birmingham. This will ensure that the main outcomes are assessed blind to intervention status. In Nepal the photographs will be assessed (i.e. ulcer size measured) in two ways. First, a research fellow, not involved in the patient's treatment, will measure the length and breadth from which area may be estimated. Second, we will use a validated software tool to measure ulcer surface area – the ARANZ tool (Silhouette Wound assessment tool). This dual assessment and dual site assessment will be of methodological interest. None of the pictures or videotapes will include patient identification information apart from the patient's trial number. From the imagery we will determine the area of the wound (cm<sup>2</sup>) at each time point and from that determine the change in surface between two observation points. The outcome is a repeated measure within each trial participant.

The above photographic observations will be taken at dressing changes twice per week during inpatient stay from intervention and control patients. The proportion of ulcers healed at 70 days is a study end point. The majority of patients will be discharged at this point. They will either return to hospital for a follow-up appointment, or a home visit will be made by the local research fellow.

Quality of life measurements will be observed fortnightly by research fellow while the patient is in hospital and then at 70 days and 6 months from randomization. We will use the Health questionnaire -EQ5D3L for this Quality of life measurement.

### **Intervention Type**

Biological/Vaccine

### **Phase**

Phase III

### **Drug/device/biological/vaccine name(s)**

Platelet enriched plasma

### **Primary outcome measure**

For all outcome measures, healing is defined as the complete re-epithelialization of the index ulcer

1. Rate of healing based on two observations per week (cm<sup>2</sup> per unit time) measured from an independent assessment and software assessment (the ARANZ tool) of photographs where a clean ruler is placed at the level of the ulcer taken during dressing changes twice weekly between baseline and 70 days
2. Proportion healed at 42 days measured by from an independent assessment and software assessment (the ARANZ tool) of photographs at 42 days
3. Time to healing (days) measured by from an independent assessment and software assessment (the ARANZ tool) of photographs from baseline to 70 days, or until the ulcer is healed

### **Secondary outcome measures**

1. Proportion healed at 70 days measured by from an independent assessment and software assessment (the ARANZ tool) of photographs at 70 days
2. Generic quality of life measured using a Nepalese version of the EuroQoL five-dimensional instrument (EQ-5D 3L) fortnightly between baseline and discharge and at 70 days
3. Long-term end-points measured at 6 months from randomization
  - 3.1. Recurrence of same/different ulcer measured using investigator notes and the Follow up

Clinical Record Form at 6 months

3.2. Anatomical changes in the limb measured using investigator notes and the Follow up Clinical Record Form at 6 months

3.3. Generic quality of life measured using a Nepalese version of the EuroQoL five-dimensional instrument (EQ-5D 3L)

4. Days hospitalized, both duration of initial admission and total, measured from patient notes at discharge and at 6 months

5. Health economic outcomes:

5.1. Number of visits to any healthcare facility from discharge to the end of follow-up assessed from patient notes at 6 months

5.2. Time taken to change dressings assessed from investigator notes during twice weekly dressing changes between baseline and discharge

**Overall study start date**

01/12/2019

**Completion date**

31/12/2023

## **Eligibility**

**Key inclusion criteria**

1. Chronic trophic ulcer on the feet or legs

2. Aged  $\geq 18$  years at the time of signing the informed consent

3. No blood-related abnormalities, haemoglobin (Hb)  $>9$  g%, and Platelets  $>100 \times 10^3 /\mu\text{l}$

4. No other health-related complications and any other severe chronic illness (such as HIV, chronic Hepatitis B, chronic Hepatitis C, or TB patients under active treatment)

5. Ulcer surface area should be between  $2 \text{ cm}^2$  and  $20 \text{ cm}^2$

6. Ulcer should be clean, dry and free from infection

7. Understands and voluntarily signs an informed consent document prior to any study-related assessments

8. Able to adhere to the study schedule and other protocol requirements

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

130

**Total final enrolment**

130

**Key exclusion criteria**

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participants from participating in the study
2. High blood pressure (>150 mmHg systolic)
3. Pregnant or breastfeeding
4. Erythema Nodosum Leprosum (ENL) or a leprosy reaction under steroid treatment
5. Any wound that has a clinical diagnosis of microbial infections

**Date of first enrolment**

15/09/2020

**Date of final enrolment**

24/05/2022

**Locations****Countries of recruitment**

Nepal

**Study participating centre****Anandaban Hospital**

The Leprosy Mission Nepal

Satdobato Road

Lalitpur

Nepal

44700

**Sponsor information****Organisation**

University of Birmingham

**Sponsor details**

Room 119

Aston Webb Building

University of Birmingham

Birmingham

England

United Kingdom

B15 2TT

+44 (0)121 4158011

researchgovernance@contacts.bham.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.birmingham.ac.uk/index.aspx>

**ROR**

<https://ror.org/03angcq70>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

UK National Institute for Health Research (NIHR) Research and Innovation for Global Health Transformation (RIGHT) Programme

## **Results and Publications**

**Publication and dissemination plan**

The results of the trial will first be reported to trial collaborators. The main report will be drafted by the trial coordinating team and the final version will be agreed by the Trial Steering Committee before submission for publication, on behalf of the collaboration.

The success of the trial depends on the collaboration of doctors, nurses and researchers from across the UK and Nepal. Equal credit will be given to those who have wholeheartedly collaborated in the trial.

We shall also feedback results to patients and communities through hospital staff who see patients on a daily basis. The Leprosy Mission has extensive experience in working with local communities and we will draw on their experience and networks to engage patients and communities within our research.

We will present our work at conferences such as the annual conference of the Neglected Tropical Disease, NGDO Network of which The Leprosy Mission is a member, Health Systems Global Conference and the International Leprosy Congress in 2022.

Tools we will use to disseminate our research output include bite-sized research reports in lay format; public announcements in communities in LMICs; policy briefings; print and online media; the director's News Blog (680+ subscribers); and institutional and professional social media accounts and websites. These forums will alert interested parties to our work, and also allow them to communicate with us.

**Intention to publish date**

30/07/2024

**Individual participant data (IPD) sharing plan**



The datasets generated during and/or analysed during the current study are/will be available upon request from Chief Investigator Professor Richard Lilford (r.j.lilford@bham.ac.uk). The data will be made available after the analysis and result dissemination is over. The data will be available for a period of 10 years after the study ends. Only anonymised data will be made available. Those accessing the data will abide by the same rules as are applicable throughout the project. Consents from participants have been already received to use the data for further research activities being held in future.

## IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		15/07/2021	03/09/2021	Yes	No
<a href="#">Results article</a>		02/05/2024	03/05/2024	Yes	No